高级检索
当前位置: 首页 > 详情页

Antitumor activity of everolimus in recurrent metastatic endometrial cancer with PTEN deletion: a case report

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Gynecology Department, Tianjin Department Medical University General Hospital, Tianjin, China [2]OrigiMed Co. Ltd, Shanghai, China [3]Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou, China [4]Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China
出处:
ISSN:

关键词: Endometrial cancer (EC) circulating tumor DNA (ctDNA) PTEN deletion everolimus case report

摘要:
Endometrial cancer (EC) is one of the most common gynecological tumors. The first-line treatment for advanced EC is chemoradiotherapy. However, patients in poor health, such as those with intestinal obstruction, have limited tolerance for the side effects of chemoradiotherapy. Individualized precision treatment may bring new hope to these patients. Herein, we have reported on a 56-year-old female patient with metastatic EC combined with severe intestinal obstruction. Due to her inability to tolerate needle biopsy and standard treatment protocols, next-generation sequencing (NGS)-based circulating tumor DNA (ctDNA) testing was performed and PTEN deletion was found. Following, the patient commenced everolimus (10 mg, qd) treatment and partial shrinkage of metastases was observed one month later. Then, everolimus (10 mg, qd) plus carboplatin (100 mg d1, 8, 15, q28d) for 2 cycles, everolimus (10 mg, qd) plus carboplatin (200 mg d1, 8, q21d) for 2 cycles, and everolimus (10 mg, qd) plus carboplatin (200 mg d1, 2, q21d) for 2 cycles were performed, and the patient got partial response for 10 months. From June 2019, the patient continued to benefit from everolimus and subsequently experienced continued benefit for more than 12 months. This is the first reported case of an EC patient who benefited from everolimus as a firstline treatment based on PTEN deletion. This case provides important clinical experience for the precision treatment of patients with advanced EC.

基金:
语种:
WOS:
PubmedID:
中科院分区:
出版当年[2021]版:
大类 | 4 区 医学
小类 | 3 区 外科
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 外科
JCR分区:
出版当年[2021]版:
Q3 SURGERY
最新[2023]版:
Q3 SURGERY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Gynecology Department, Tianjin Department Medical University General Hospital, Tianjin, China
通讯作者:
通讯机构: [4]Department of Medical Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China [*1]Department of Medical Oncology, The Fourth Hospital of Hebei Medical University, 12 Health Road, Shijiazhuang 050011, China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:39770 今日访问量:0 总访问量:1333 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 河北医科大学第四医院 技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号